Kymera Therapeutics’ Post

Thrilled to announce the release of Microba Life Sciences Q3 FY24 Activities Report and 4C Report to the ASX today. This quarter, Microba achieved the following significant milestones: Revenue Growth: We're excited to report strong revenue growth this quarter (82% QoQ/297% YoY), demonstrating the increasing market demand for our world-leading microbiome tests and products. World-First Innovation: We launched the MetaPanel pathogen test in Australia alongside Sonic Healthcare, a game-changer in accurate pathogen detection. Strategic Expansion: Positive progress continues on the integration of our acquisition of UK-based Invivo Healthcare, solidifying our presence in the UK market. Therapeutic Pipeline Progression: We're maintaining momentum across all 3 of our therapeutic programs, advancing the development of life-changing treatments. Get the full details on these exciting developments in our Quarterly Report and Investor Presentation, links below. Quarterly Activities Report - https://loom.ly/kdjD7-Q Investor Presentation - https://loom.ly/mWLSWcU #Microbiome #LifeSciences #Innovation #Healthcare #ASX

Such a dynamic panel discussion including perspectives from Stuart McGahie, Philippe Guisset, Aswathi Padman and Niklas Mellerup, led by Anni Neumann, about how our experts are harnessing Next-Best-Action strategies to empower the field force #REpharma2024

🧬🌟 Just stumbled again upon a note I took in November about what I believe is THE most valuable source of insights and information in the biopharma sector! 🎥💡 Check out @BruceBooth on https://buff.ly/4aYMNA4. It's packed with deep dives into the latest trends that are shaping our industry. Whether you're a seasoned professional or just curious about the biopharma and VC worlds, this video is a goldmine of knowledge. 🤓📚 #BiopharmaInsights #HealthcareInnovation #MustWatch #BiotechTrends #BiopharmaCommunity

Loving the energy at the Swiss BioTech Day! I am still excited from the great connections and fascinating scientific discussions I had! Here are my key takeaways: ⭐Innovation & Regulation: Swissmedic and ANVISA panel showed the importance of involving regulatory bodies early in the innovation process. It's crucial for ensuring that groundbreaking ideas gain acceptance from regulators. ⭐Public Communication: communicate innovations to the general public is often overlooked but it is key. Clear explanations can drive and accelerate market adoption. ⭐Investment in Innovation: Innovators and investors must understand each other. A clear pitch deck and a solid go-to-market strategy can significantly speed up decision-making. A huge shoutout to Daniela Marino from CUTISS AG for showcasing groundbreaking science in personalized skin technology. DenovoSkin is set to transform the treatment of large skin injuries, revolutionizing burn recovery. #SwissBioTechDay #Innovation #Science #Networking 

Microba is pleased to provide a summary of its activities for the quarter ended 31 March 2024. See here for the full Quarterly Investor Presentation: https://loom.ly/mWLSWcU See here for the full Quarterly Activities Report: https://loom.ly/kdjD7-Q With strong sales and revenue growth in Australia, plus significant progress on the integration of recently acquired UK-based Invivo Healthcare and world-first innovation through the launch of the MetaPanel™ pathogen detection test with Sonic Healthcare, Microba continues to transform human health and combat disease through precision microbiome science. Alongside this we continue to gain momentum across all three of our therapeutic programs - IBD, Auto-Immune and Immuno-Oncology – advancing the development of life-changing treatments to address numerous unmet clinical needs. Investors with complete Microba Investor Hub accounts can submit questions via this link: https://loom.ly/nZ0-_Sk

As the event is getting closer, we are getting more and more excited 🤩 We're certain that you are too! Thus, here we’ve provided you with a brief overview of the agenda for the upcoming talk by Biobridge Partners.  You can sign up here: bit.ly/3Zmpzi0 NB: Make sure to stay for the 30-minute networking session from 18:30 until 19:00 🕖. #cbs #cbshealth #studentorganization #biobridgepartners #consultancy #lifescience #strategyconsultancy

#AVBCC2023 is only 4 short weeks away. As a stakeholder in the cancer-care value equation, this is one meeting you shouldn't miss—have you made your plans to join us for this must-attend event? Take a glimpse at what we have on the agenda: · Keynote sessions led and moderated by visionaries in the industry: Scott Gottlieb, MD; Joe Grogan, JD; and Adam Fein, PhD. · Key Opinion Leader sessions where expert faculty and experienced practitioners guide an in-depth exploration and discussion. · Sessions on current and emerging trends like #PrecisionMedicine’s Role in Ensuring Accurate Diagnosis and Treatment, Pharma and Value-Based Agreements, #EconomicTrends, and more! If these sound like conversations you want to be part of, register virtually or request your live invite: https://lnkd.in/e37zKq5A

What are the challenges the industry faces in becoming more sustainable, and how are we helping to address them? Listen to this short interview with our Head of R&D at last week's Advanced Therapies. ⬇

🚀 Join us & Ludovic d’Aprea, CEO Solution for Enterprise Imaging, GE HealthCare, at an exciting panel discussion at HLTH Europe in Amsterdam! 🗓️ 20 June 2024, 10:40 AM – 11:20 AM CEST / Aroma Stage 🎤 Topic: Goldmine or fool’s gold? Extracting value from health data Data has revolutionized industries from finance to retail. Healthcare data has the potential to transform our lives even more but remains underutilized, siloed, and mired in ethical debate. We need to move the conversation forward to unlock this potential. Where can data make the biggest impact in healthcare, and how do we access this goldmine? Don’t miss this discussion on transforming healthcare through data. See you there! #HealthData #GEHC #GEHealthCare #hltheurope